Buy and hold this ASX dividend legend up 900% over 25 years

This stock has delivered healthy returns for shareholders.

| More on:
Doctor doing a telemedicine using laptop at a medical clinic

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ASX dividend share Sonic Healthcare Ltd (ASX: SHL) has delivered excellent returns for long-term investors.

Since January 1999, the Sonic Healthcare share price has risen by close to 900%. However, it's also true to say that the stock has dropped more than 40% since December 2021. I believe this sell-off is a good time to invest in the ASX healthcare share.

Past performance is not necessarily a reliable indicator of future performance – I'm not expecting the global pathology company's share price to rise by another 900% in the next 25 years.

But, a combination of good organic growth, global acquisitions and a shareholder focus could be appealing for the foreseeable future.

Passive income credentials

The company's board has a progressive dividend policy. In other words, the directors want to increase the dividend each year for investors if the profit, balance sheet and business conditions enable it to.

There are not many businesses on the ASX that have grown their dividends every year in a row for at least a decade. The ASX dividend legend has increased its payout annually since 2013.

But the company's impressive dividend credentials stretch back further than its current streak. The business increased its annual dividend per share every year between 1994 and 2010. It paid an annual dividend per share of 59 cents between 2010 and 2012 and then started increasing the dividend again in 2013 when the payout was hiked to 62 cents per share.

In other words, it has grown or maintained its dividend every year since 1994, and its payout was maintained for just two of those years.

In FY24, the company grew its annual payout by 1.9% to $1.06 per share, which translates into a current dividend yield of 3.9%, excluding franking credits.

Good time to invest in the ASX dividend legend

Optimism about the company has suffered as its profitability took a hit due to elevated costs due to inflation and the winding down of COVID testing revenue.

The company noted that its operating profit (EBITDA) margin improved in the second half of FY24 compared to the first half, suggesting a "return to margin expansion".

Sonic Healthcare is expecting its EBITDA to rise approximately 10% in FY25, supported by ongoing revenue growth, cost control and operating leverage.

In FY24, the ASX dividend share achieved base business organic revenue growth of 6%, which I think is a solid increase and doesn't take into account the bonus of the acquisitions in places like Switzerland and Germany. Sonic reported total base business revenue growth of 16% in FY24.

Sonic Healthcare is expecting future margins and overall profit to increase due to synergies from acquisitions, new contracts, lower inflation, technology investments, and more.

The company noted at the time of its FY24 results that further acquisition and contract opportunities were under consideration.

At the current Sonic Healthcare share price, I think it's a solid long-term buy, particularly if it can implement more technology (such as AI) throughout its operations.

Should you invest $1,000 in Sonic Healthcare Limited right now?

Before you buy Sonic Healthcare Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Sonic Healthcare Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor Tristan Harrison has positions in Sonic Healthcare. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Sigma share price up 9% on first day of trading post-merger with Chemist Warehouse

It's a post-merger party for Sigma Healthcare shareholders today.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 135% in a year, why this ASX 200 healthcare stock is 'on track to become a truly great Australian success'

A leading fund manager expects more strong performance from this surging ASX 200 healthcare stock.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

With revenue up 9%, why does the NIB share price keep falling?

Will the ailing share price make a full recovery?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Guess how much $5,000 invested in Sigma shares in December 2023 is worth now!

Sigma shares have soared over the past year alongside the merger with Chemist Warehouse.

Read more »

Woman with headphones on relaxing and looking at her phone happily.
Healthcare Shares

Everything you need to know about the latest CSL dividend

CSL's latest dividend should be turning investors' heads...

Read more »

thoughtful investor sitting at computer
Healthcare Shares

What are brokers saying about CSL shares after the selloff?

The biotech giant's shares hit a 52-week low yesterday. Is this a buying opportunity?

Read more »

A man looking at his laptop and thinking.
Earnings Results

CSL shares push higher despite 'mixed result with headline misses'

There were positives and negatives in the company's first half performance.

Read more »

Scientists working in the laboratory and examining results.
Earnings Results

CSL share price on watch amid $2.1b half year profit and dividend hike

Let's see how this biotech giant performed during the first half of FY 2025.

Read more »